EW vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EW and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
EW is a standard domestic listing, while SNY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | EW | SNY |
|---|---|---|
| Company Name | Edwards Lifesciences Corporation | Sanofi |
| Country | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 44.47 billion USD | 120.08 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 27, 2000 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of EW and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EW | SNY |
|---|---|---|
| 5-Day Price Return | -1.19% | -0.53% |
| 13-Week Price Return | -1.88% | 0.51% |
| 26-Week Price Return | 3.78% | -7.46% |
| 52-Week Price Return | 17.35% | -16.73% |
| Month-to-Date Return | -2.61% | 7.69% |
| Year-to-Date Return | 2.31% | -9.76% |
| 10-Day Avg. Volume | 4.54M | 2.37M |
| 3-Month Avg. Volume | 4.23M | 1.95M |
| 3-Month Volatility | 20.42% | 33.01% |
| Beta | 0.96 | 1.05 |
Profitability
Return on Equity (TTM)
EW
41.25%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
EW’s Return on Equity of 41.25% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
SNY
14.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EW
72.96%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
EW’s Net Profit Margin of 72.96% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
SNY
20.51%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EW
25.01%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
An Operating Profit Margin of 25.01% places EW in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
SNY
19.08%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EW | SNY |
|---|---|---|
| Return on Equity (TTM) | 41.25% | 14.92% |
| Return on Assets (TTM) | 31.58% | 8.49% |
| Net Profit Margin (TTM) | 72.96% | 20.51% |
| Operating Profit Margin (TTM) | 25.01% | 19.08% |
| Gross Profit Margin (TTM) | 78.87% | 71.85% |
Financial Strength
Current Ratio (MRQ)
EW
4.68
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
EW’s Current Ratio of 4.68 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
SNY
1.27
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EW
0.06
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
Falling into the lower quartile for the Health Care Equipment & Supplies industry, EW’s Debt-to-Equity Ratio of 0.06 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
SNY
0.32
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EW
3.15
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
In the lower quartile for the Health Care Equipment & Supplies industry, EW’s Interest Coverage Ratio of 3.15 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EW | SNY |
|---|---|---|
| Current Ratio (MRQ) | 4.68 | 1.27 |
| Quick Ratio (MRQ) | 3.79 | 0.94 |
| Debt-to-Equity Ratio (MRQ) | 0.06 | 0.32 |
| Interest Coverage Ratio (TTM) | 3.15 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
EW currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SNY
4.65%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.65%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
EW
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
EW has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | EW | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.65% |
| Dividend Payout Ratio (TTM) | 0.00% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
EW
10.63
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
EW’s P/E Ratio of 10.63 is below the typical range for the Health Care Equipment & Supplies industry. This may indicate that the stock is potentially undervalued, or it could reflect market concerns about the company’s future prospects.
SNY
9.38
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 9.38 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EW
7.75
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
EW’s P/S Ratio of 7.75 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
SNY
1.93
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
SNY’s P/S Ratio of 1.93 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EW
4.35
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
EW’s P/B Ratio of 4.35 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SNY
1.44
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EW | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 10.63 | 9.38 |
| Price-to-Sales Ratio (TTM) | 7.75 | 1.93 |
| Price-to-Book Ratio (MRQ) | 4.35 | 1.44 |
| Price-to-Free Cash Flow Ratio (TTM) | 58.01 | 10.27 |